Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-DYRK1B Recombinant Antibody (D2019) (V2LY-0425-LY1154)


See all DYRK1B antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat, Dog, Cattle
Clone
D2019
Antibody Isotype
IgG1, κ
Application
WB, IP, IF, ELISA

Basic Information

Immunogen
Amino acids 501-539 within an internal region of human Dyrk1B.
Host Species
Mouse
Specificity
Human, Mouse, Rat, Dog, Cattle
Antibody Isotype
IgG1, κ
Clonality
Monoclonal Antibody
Application Notes
ApplicationNote
ELISA1:100-1:1,000
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
Gelatin & PBS
Preservative
Sodium Azide
Concentration
0.2 mg/ml
Purity
>95% as determined by analysis by SDS-PAGE
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B
Entrez Gene ID
Human9149
Mouse13549
Rat308468
UniProt ID
HumanQ9Y463
MouseQ9Z188
RatD4ACC4
Research Area
Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. Enhances the transcriptional activity of TCF1/HNF1A and FOXO1. Inhibits epithelial cell migration. Mediates colon carcinoma cell survival in mitogen-poor environments. Inhibits the SHH and WNT1 pathways, thereby enhancing adipogenesis. In addition, promotes expression of the gluconeogenic enzyme glucose-6-phosphatase catalytic subunit 1 (G6PC1).
Biological Process
Adipose tissue development Source: UniProtKB
Myoblast fusion Source: Ensembl
Peptidyl-serine phosphorylation Source: GO_Central
Peptidyl-threonine phosphorylation Source: GO_Central
Positive regulation of transcription, DNA-templated Source: UniProtKB
Protein autophosphorylation Source: InterPro
Protein phosphorylation Source: UniProtKB
Cellular Location
Nucleus
Involvement in disease
Abdominal obesity-metabolic syndrome 3 (AOMS3):
A form of abdominal obesity-metabolic syndrome, a disorder characterized by abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol, high blood pressure, and elevated fasting glucose levels. AOMS3 is characterized by early-onset coronary artery disease, central obesity, hypertension, and diabetes.
PTM
Autophosphorylated on tyrosine residues. Phosphorylated by MAP kinase. Tyrosine phosphorylation may be required for dimerization.
More Infomation

Bhat, N., Narayanan, A., Fathzadeh, M., Kahn, M., Zhang, D., Goedeke, L., ... & Mani, A. (2022). Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. The Journal of Clinical Investigation, 132(3).

Zhuang, L., Jia, K., Chen, C., Li, Z., Zhao, J., Hu, J., ... & Yan, X. (2022). DYRK1B-STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation, 145(11), 829-846.

Bhat, N., Narayanan, A., Fathzadeh, M., Shah, K., Dianatpour, M., Abou Ziki, M. D., & Mani, A. (2022). Dyrk1b promotes autophagy during skeletal muscle differentiation by upregulating 4e-bp1. Cellular Signalling, 90, 110186.

Papenfuss, M., Lützow, S., Wilms, G., Babendreyer, A., Flaßhoff, M., Kunick, C., & Becker, W. (2022). Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B. Scientific reports, 12(1), 1-15.

Lee Walmsley, D., Murray, J. B., Dokurno, P., Massey, A. J., Benwell, K., Fiumana, A., ... & Hubbard, R. E. (2021). Fragment-derived selective inhibitors of dual-specificity kinases DYRK1A and DYRK1B. Journal of Medicinal Chemistry, 64(13), 8971-8991.

Dong, C., An, L., Yu, C. H., & Huen, M. S. (2021). A DYRK1B-dependent pathway suppresses rDNA transcription in response to DNA damage. Nucleic acids research, 49(3), 1485-1496.

Chang, C. C., Chiu, C. C., Liu, P. F., Wu, C. H., Tseng, Y. C., Lee, C. H., & Shu, C. W. (2021). Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells. Cancers, 13(22), 5779.

Dong, C., West, K. L., Tan, X. Y., Li, J., Ishibashi, T., Yu, C. H., ... & Huen, M. S. (2020). Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin. Proceedings of the National Academy of Sciences, 117(29), 17019-17030.

Yousefelahiyeh, M., Xu, J., Alvarado, E., Yu, Y., Salven, D., & Nissen, R. M. (2018). DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B. PloS one, 13(11), e0207779.

Becker, W. (2018). A wake‐up call to quiescent cancer cells–potential use of DYRK 1B inhibitors in cancer therapy. The FEBS Journal, 285(7), 1203-1211.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-DYRK1B Recombinant Antibody (D2019)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quote Online Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry